Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of (11)C-Labeled ALK2 Inhibitors

von Murrell, Emily, Tong, Junchao, Smil, David, Kiyota, Taira, Aman, Ahmed M., Isaac, Methvin B., Watson, Iain D. G., Vasdev, Neil
Veröffentlicht in ACS Med Chem Lett (2021)

Antagonists of the serotonin receptor 5A target human breast tumor initiating cells

von Gwynne, William D., Shakeel, Mirza S., Girgis-Gabardo, Adele, Kim, Kwang H., Ford, Emily, Dvorkin-Gheva, Anna, Aarts, Craig, Isaac, Methvin, Al-awar, Rima, Hassell, John A.
Veröffentlicht in BMC Cancer (2020)

Sorafenib as an Inhibitor of RUVBL2

von Nano, Nardin, Ugwu, Francisca, Seraphim, Thiago V., Li, Tangzhi, Azer, Gina, Isaac, Methvin, Prakesch, Michael, Barbosa, Leandro R. S., Ramos, Carlos H. I., Datti, Alessandro, Houry, Walid A.
Veröffentlicht in Biomolecules (2020)

PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma

von Babichev, Yael, Kabaroff, Leah, Datti, Alessandro, Uehling, David, Isaac, Methvin, Al-awar, Rima, Prakesch, Michael, Sun, Ren X., Boutros, Paul C., Venier, Rosemarie, Dickson, Brendan C., Gladdy, Rebecca A.
Veröffentlicht in J Transl Med (2016)

Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma

von Ensan, Deeba, Smil, David, Zepeda-Velázquez, Carlos A., Panagopoulos, Dimitrios, Wong, Jong Fu, Williams, Eleanor P., Adamson, Roslin, Bullock, Alex N., Kiyota, Taira, Aman, Ahmed, Roberts, Owen G., Edwards, Aled M., O’Meara, Jeff A., Isaac, Methvin B., Al-awar, Rima
Veröffentlicht in J Med Chem (2020)